The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Analysis of first-line treatment (tx) patterns in advanced non-small cell lung cancer (NSCLC) patients (pts) with compromised performance status (PS), organ dysfunction (dfxn) or other significant comorbidities.
 
Julia Judd
No Relationships to Disclose
 
Elizabeth A. Handorf
Honoraria - NCCN/Pfizer
Research Funding - NCCN/Lilly (Inst); Pfizer (Inst); Pfizer (Inst)
 
Brinda Gupta
No Relationships to Disclose
 
Martin Edelman
Stock and Other Ownership Interests - Biomarker Strategies
Consulting or Advisory Role - Flame Biosciences; Kanaph Therapeutics; Precision Oncology; Sanofi/Regeneron; WindMIL
Research Funding - Apexigen (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Nektar (Inst); United Therapeutics (Inst); Windmil (Inst)
Patents, Royalties, Other Intellectual Property - Patent application for radiopharmaceutical to treat small cell lung cancer. (Inst)
Travel, Accommodations, Expenses - Nektar
Other Relationship - AstraZeneca/MedImmune; Boehringer Ingelheim; Seagen; Takeda